Most Recent Articles by Carlos Harrison
A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.
Progressive telomere shortening during successive cell divisions is thought to contribute to phase transition in chronic myeloid leukemia.
Researchers are promoting physician and patient awareness about the potential tie between depression and certain therapies.
Using Autologous Tumor-Infiltrating Lymphocytes to Mediate Tumor Regression: Promising Outcomes in Experimental ResearchJul 30, 2018
Experimental research may provide a blue print for the treatment of many types of cancer.
Though early-stage bladder cancer is infrequently fatal, the decrease in recurrence rates has a meaningful impact on the quality of life for patients as well as treatment costs.
More Articles by Carlos Harrison
Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage DiagnosisJun 19,2018
Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for InhibitionJun 18,2018
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Changes in Renal Cell Carcinoma Pathologic Staging and Histologic Grading
- Palbociclib Plus Letrozole Did Not Show Clinical Benefit in PALLET Trial
- Differences in Treatment Site of Care: Why Is My Insurer Sending Me to a Particular Treatment Center?
- Adjuvant Erlotinib May Benefit Patients With Early-Stage Non-Small Cell Lung Cancer
- Lower-Dose, Shorter-Duration Chemotherapy Regimens: Is This a Trend?
- CD19 CAR T-Cell Therapies: "Expect an Evolution"
- Hypofractionated WBI Found Noninferior to Conventionally Fractionated WBI
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis